Business Partners

Hisamitsu Pharmaceutical Co., Inc. is Noven's parent company. Hisamitsu is a leading pharmaceutical company that develops and markets prescription and over-the-counter ("OTC") pharmaceutical products using transdermal delivery systems technology. Its leading product in prescription pharmaceuticals is its Mohrus^® series (ketoprofen patch for pain), and its leading brand in the OTC business is Salonpas^®. The company was founded in 1847 and is located in Saga, Japan. Noven serves as Hisamitsu's U.S. growth platform in prescription pharmaceuticals. Additional information is available through Hisamitsu's corporate website at http://www.hisamitsu.co.jp/english.

Novogyne Pharmaceuticals (a.k.a. Vivelle Ventures LLC) is a women's health products company jointly owned by Noven and Novartis Pharmaceuticals. Novogyne's products include Vivelle-Dot^®, the world's smallest estrogen patch and the most dispensed estrogen patch in the U.S., and CombiPatch^®, the first combination HT patch approved in the U.S. Novogyne has 120 sales representatives targeting U.S. physicians who frequently prescribe hormone therapy products.

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of $ 50.6 billion, while approximately USD 9.1 billion was invested in R&D throughout the Group. Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com/.

Apotex Corp. is an innovative global research and technology leader in generic pharmaceuticals. Apotex has over 6,500 employees worldwide and produces over 300 medicines in 4,000 dosages, in 21 facilities in North America. Ranked among the top 10 generic companies in the U.S., Apotex presently has 600 products in development, and produces quality affordable medicines for healthcare systems in 115 countries. Apotex markets and sells Noven's generic Fentanyl Transdermal System in the U.S.